Castle Biosciences, Inc. CSTL
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Sep 15, 2026positive TissueCypher simulated use study showed significantly increased appropriate management aligned with progression outcomes across patients with NDBE, IND and LGD.
In the study, simulated use of TissueCypher significantly increased appropriate management aligned with known progression outcomes across patients with NDBE, indefinite for dysplasia (IND) and low-grade dysplasia (LGD).
Filing - Mar 13, 2026positive Prospective multicenter DECIDE Study showed DecisionDx-Melanoma i31-SLNB accurately predicts sentinel lymph node positivity with patients <5% predicted risk having only 2.6% actual SLN positivity.
New data from Castle's ongoing prospective multicenter study evaluating DecisionDx-Melanoma's i31-SLNB test result show the test accurately predicts SLN positivity, outperforms staging criteria and other GEP tests, and identifies patients below the 5% NCCN threshold who may safely forgo SLNB with fa
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.